Factor | Studies | |
Previous attacks | ↑ Number of previous attacks/ED admissions/hospitalisations | 22 25 83 89–91 |
Disease severity | ↓ FEV1/↑ airway obstruction | 23 89 90 |
↑ GINA Step | 23 | |
Disease control | High Asthma Control Questionnaire score | 14 23 |
Poor asthma control | 91 92 | |
Treatment | ↑ Reliever/SABA use | 23 89 |
↑ Previous courses of oral corticosteroids | 89 | |
Fixed dose steroid versus steroid in maintenance and reliever therapy | 90 | |
Poor treatment adherence | 93 | |
Incorrect inhaler technique | 94 | |
Inhaler device polypharmacy | 83 | |
Co-prescription of non-steroidal anti-inflammatory drugs | 95 | |
Demographic factors | Female gender | 25 89 90 95 |
Increased age | 25 89 95 | |
Ethnicity: Black | 91 | |
Comorbidities | Smoking | 22 89 95 |
Gastro-oesophageal reflux disease | 25 89 95–97 | |
Rhinitis, nasal polyps, eczema | 89 95 | |
Rhinitis | 25 | |
Chronic sinusitis | 14 96 97 | |
Obesity | 23 89 96 98 | |
Depression | 83 95 97 | |
Vocal cord dysfunction | 83 | |
Obstructive sleep apnoea | 83 97 | |
Recurrent respiratory infections | 97 | |
Inflammation/phenotype | ↑ Blood eosinophil count | 89 95 96 |
↑ Bronchodilator responsiveness | 96 |
Listed studies: Fuhlbrigge et al,10 Bateman et al,23 Patel et al,90 Blakey et al,89 Loymans et al,22 TENOR,91 Kang et al,25 McDonald et al,83 Bateman et al,92 Engelkes et al,93 Melani et al,94 Price et al,95 Denlinger et al,96 ten Brinke et al,97 Fitzpatrick et al 98.
GINA, Global Initiative for Asthma; SABA, short-acting β-agonist.